Deficiency of lysosomal TMEM175 in myeloid macrophages exerts anti-tumor immunity via inflammasome and cross-presentation pathway - PubMed
8 days ago
- #immunotherapy
- #TMEM175
- #macrophages
- Deficiency of lysosomal TMEM175 in myeloid macrophages enhances anti-tumor immunity.
- TMEM175 knockout in macrophages inhibits tumor growth and metastasis by promoting M1-like polarization and reducing M2-like polarization.
- Enhanced recruitment and activation of T cells and NK cells in the tumor microenvironment (TME) due to TMEM175 deficiency.
- Anti-tumor effects are mediated via inflammasome (caspase-1, IL-1β, IL-18) and cross-presentation pathways.
- Tmem175-/- BMDMs show improved tumor antigen cross-presentation, further enhanced by IL-1β and IL-18.
- NLRP3 inflammasome activation in Tmem175-/- BMDMs occurs through lysosomal permeabilization and cathepsin B leakage.
- Tmem175-/- mice exhibit better responsiveness to anti-PD-1 therapy.
- TMEM175 is identified as a potential target for cancer immunotherapy.